Feature | May 15, 2009 | William Shea, M.D.

CCTA to Jump Hurdles

While growth for disruptive technologies is coming, it’s all about timing.

Stock image

The majority of respondents believe that CT volumes will increase in 2009. Most facilities do not plan to purchase CT scanners in the next year. The difference between smaller imaging systems and larger imaging systems is not statistically significant.

 TMTG Logo

The MarkeTech Group (TMTG) conducted a poll of its imagePRO opt-in panel of over 600 U.S.-hospital based imaging administrative directors and managers. Manuel Andrade, TMTGs research analyst, made the analysis.

Many experts lauded multidetector computed tomography (MDCT) and cardiac computed tomography angiography (CCTA) as disruptive technologies that would abruptly alter the standard of care for those with coronary artery disease. Now, years later, CCTA is slowly gaining acceptance in the medical community, both by providers, payers and administrators. Why so slowly? Perhaps the answer is simply timing. What are the hurdles? The ones that play a role include cost, radiation safety, the economy and the need for evidence-based clinical outcomes. Cost of Healthcare In the last decade, the cost of healthcare in the U.S. and especially medical imaging has skyrocketed. Expensive diagnostic exams became a target for cost containment, which would explain the non-coverage determinant for CCTA by CMS in December 2007, and the ensuing coverage confusion that followed. CMS and the insurance industry simply will not support the use of CCTA as another layer of cost. Any medical center or practice interested in developing a cardiac imaging program adopted a conservative approach. At the date of this writing, all local Medicare intermediaries and most commercial payers do reimburse for CCTA. However, reimbursement is based on Local Coverage Determinants that vary greatly in the details, and it is the attention to these details that determines appropriate reimbursement. CMS has solicited requests for input into CPT code development, but until there is a clear demonstration that CCTA is cost effective and adds value, we still face the cost restraints that are in place. Radiation Safety Secondary effects of radiation exposure are top of mind in the medical community and the general public. Several peer review studies and editorial reviews have highlighted the risks of inadvertent over-utilization of CT scanning, especially in the younger population. To address this issue, the ACR has adopted the “Image Gently” program, and manufacturers have developed dose reduction strategies. Excellent articles like those from Mayo, et al, (AJR) have delineated the risks when imaging is appropriately performed. We will need to continually monitor this issue and ensure that the appropriate utilization of MDCT prevails. Economic Recession Obviously, no one predicted the sudden global collapse of the economy last year. This has further limited growth of CCTA programs. Capital budgets have been slashed, purchases put on hold and FTEs dismissed. Systems must be efficient and, at the very least, cost neutral or they face the piper. While this is no time for expansion into an arena with questionable reimbursement, fortunately, recent studies have demonstrated cost savings when CCTA is used appropriately. For example, in the ED setting, a negative CCTA allows for safe and rapid discharge, saving a great deal of expense in unnecessary admissions and time of stay. In the office setting, those patients with a confusing presentation can be carefully evaluated with CCTA, reducing the number of more invasive and expensive catheterizations. Need for Evidence-Based Clinical Outcomes The recent National Forum on “Appropriate Coverage of Coronary CT Angiography,” organized and sponsored by the SCCT, brought together influential providers and payers to discuss the issues currently surrounding CCTA usage. Payers perceive a lack of evidence that CCTA improves clinical outcomes. This exam must demonstrate this benefit before reaching acceptance. But how do we measure an improved outcome? There are no definable metrics in place, but rapid and safe discharge, decreased utilization of downstream imaging, and modified patient behavior are being studied. Prospective randomized multi-institutional studies are expensive (especially in this economy) and time-consuming, but must be performed and must confirm these benefits. So while we must continue to cross these hurdles, the one positive aspect is that they have brought together many groups in a collegial and cooperative way in an effort to educate our industry, medical colleagues and our patients to the potential benefits of this wonderful new capability. It is up to us to jump these hurdles as quickly as possible. For more information: The MarkeTech Group

Related Content

Canon Aquilion One CT Helps Gates Vascular Institute Adhere to New Stroke Guidelines
News | Computed Tomography (CT) | December 12, 2018
In stroke, time saved on imaging is time gained in the treatment window. The recently updated guidelines from the...
Coreline Soft Introduces AI Lung Segmentation Solution at RSNA 2018
News | Lung Cancer | December 10, 2018
December 10, 2018 — Korean image software company Coreline Soft Co. Ltd.
FDA Approves New Features for Planmed Verity Cone Beam CT Scanner
Technology | Computed Tomography (CT) | December 07, 2018
The U.S. Food and Drug Administration (FDA) issued an approval letter for the new features and intended uses of the...
YITU Releases AI-Based Cancer Screening Solutions at RSNA 2018
News | Artificial Intelligence | December 06, 2018
Chinese artificial intelligence (AI) healthcare company YITU healthcare released two brand-new products, Intelligent...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
GE Healthcare Unveils New Applications and Smart Devices Built on Edison Platform
Technology | Artificial Intelligence | December 05, 2018
GE Healthcare recently announced new applications and smart devices built on Edison – a platform that helps accelerate...
Infervision Introduces AI Capabilities for Chest CT Reading
Technology | Computer-Aided Detection Software | November 30, 2018
Big data and artificial intelligence (AI) company Infervision announced the launch of InferRead CT Chest, a new product...
NeuroLogica and MaxQ AI Announce Distribution Agreement
News | Stroke | November 30, 2018
Clinical diagnostics intelligence platform company MaxQ AI and Samsung NeuroLogica announced a distribution agreement...
Videos | Advanced Visualization | November 30, 2018
This is an example of the FDA-cleared OpenSight augmented reality (AR) system for surgical planning from NovaRad at t